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In the recent months, a number of transcriptomic studies have generated high-resolution data on the genes and pathways 
that are dysregulated in the patients infected with SARS-CoV-2 and enriched our understanding of the disease biology of 
this novel viral infection. The cumulative evidence collected from these data are considered in this article. Three motifs 
emerge with potential for future research and clinical translation. First, instead of a broad cytokine storm, one needs to 
interrogate the disease in terms of timing of specific cytokine up-regulation. Second, there is a subpopulation of immature or 
developing neutrophils in the patients with severe COVID-19 illness. This needs to be probed further for mechanistic insight 
and possible drug targets. Third, complement and coagulation cascades are significantly dysregulated in COVID-19, leading 
to the common clinical observation of a hypercoagulable state being associated with poor outcome. Interactions of these 
pathways with other immune-inflammatory pathways are important areas of future research. Finally, with rapid advances in 
relevant technologies in medicine (clinical transcriptomics, systems biology and artificial intelligence), we envisage 
deployment of these platforms in the clinical laboratory which shall benefit timely management of critical infectious 
illnesses such as COVID-19 and sepsis. 
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Introduction 
The emergence of the corona virus disease 2019 
(COVID-19) pandemic has made the scientific 
community scramble for answers. In addition to the 
virulence of Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2), variation in the host 
response has been considered an important 
contributor to outcome of the infection
1–3
. In this 
context, transcriptomic profiling has emerged as a 
powerful tool to dissect the host perturbation induced 
by an infection, i.e., genome-scale disease biology of 
COVID-19. In this approach, one measures the level 
of gene expression (i.e., transcript abundance) of the 
entire host genome, and performs unbiased analysis 
that enables discovery of pathways and processes not 
visible by candidate gene approach. Here, we discuss 
some recent studies illuminating the human host 
response to SARS-CoV-2, followed by the biological 
and clinical implication of these discoveries. The 
findings from these studies complement those from 
other important areas of research, such as, vaccine 
development and novel therapeutics. 
Multiple studies on the COVID-19 transcriptome 
have generated plethora of data and provided insights 
into different aspects of the disease biology. List of 
the questions that have been answered by the recent 
transcriptome studies are presented in (Box 1). Most 
of the studies have performed transcriptome profiling 
by RNA sequencing (RNA seq) that generates the 
expression data of the entire human genome. This 
enables unbiased and deep analysis and exploration of 
differential and co-expression structures in the data 
space. A complementary approach takes into account 
those genes prioritized for an infectious disease 




Single-cell RNA-sequencing (scRNA seq) is 
becoming more common and has been performed by 
many authors
2,4
. This technique, i.e., scRNA seq, 
differs from the more familiar bulk RNA sequencing 
in some important ways. Both techniques start with a 
sample of the heterogeneous tissue (consisting of 
multiple cell types). However, in bulk RNA seq 
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DNA (cDNA) is extracted from the sample followed 
by sequencing of the RNA molecules, leading to an 
estimate of the average transcript abundance in the 
sample. On the other hand, in the scRNA seq method, 
barcoding is done for single-cell origin of the cDNAs. 
Consequently, after sequencing of cDNA, methods 
for dimensionality reduction (such as clustering or 
principal components analysis) are performed to 
identify cell types associated with higher or lower 
levels of gene expression. While bulk RNA seq can 
identify differences in average transcript abundance 
between two samples, scRNA seq can identify 
differences in gene expression levels between specific 
cells of two samples. Also, scRNA seq can detect 
transcriptional differences between specific cell types 
(especially, if these are rare cell types in the given 
tissue), even when bulk RNA seq shows no difference 
in average gene expression levels. 
Generation of high-dimensional data by scRNA seq 
for each subject offers the opportunity to explore the 
cellular context of the association between specific 
transcripts and the clinico-pathological phenotype of 
interest. For COVID-19, identification of the immune 
cells associated with severity or outcome is motivated 
by the quest for diagnostic/prognostic biomarkers (for 
stratification of the patients) and immunomodulatory 
therapy (either boosting appropriate and suppressing 
harmful cellular processes). Some key results from 
these studies are listed in the next section.  
One of the first studies was done by Blanco-Melo 
and colleagues who compared the host response to 
SARS-CoV-2 versus other respiratory viruses, such as 
Middle East respiratory syndrome-related coronavirus 
(MERS-CoV), severe acute respiratory syndrome 
related coronavirus 1 (SARS-CoV-1), human 
parainfluenza virus 3 (HPIV3), respiratory syncytial 
virus (RSV) and influenza A virus (IAV), using cell 
and animal models in addition to transcriptional and 
serum profiling of patients
5
. Host response to an 
infection was shown to be very different between 
SARS-CoV-2 and other respiratory viruses. In the 
patients infected with SARS-CoV-2, there was an 
inappropriate response to the infection including low 
type I and III interferon signalling but high levels of 
pro-inflammatory cytokines/chemokines such as 
interleukin 6 (IL-6), interleukin 1 receptor type 1 
(IL1RA), monocyte-recruiting C-C motif chemokine 
ligand 2 (CCL2), C-C motif chemokine ligand 8 
(CCL8) and neutrophil chemoattractant C-X-C motif 
chemokine ligand 2 (CXCL2), C-X-C motif 
chemokine ligand 8 (CXCL8). The authors concluded 
that an imbalanced host response to SARS-CoV-2 
comprising reduced innate antiviral response failing 
to clear the pathogen combined with harmful 
inflammatory response constitute a hallmark of 
COVID-19 disease process. 
Wilk and colleagues sought to provide a cell atlas 
of the peripheral immune response to severe COVID-
19
2
. Single cell RNA sequencing was performed on 
peripheral blood mononuclear cells (PBMC) from six 
healthy donors and seven patients suffering from 
COVID-19 (including four patients with acute 
respiratory distress syndrome). A major finding was 
reconfiguration of peripheral immune cell phenotype 
including a heterogeneous interferon-stimulated gene 
signature, HLA class II downregulation and a 
developing neutrophil population, closely related to 
plasmablasts. Cellular trajectory analysis revealed a 
differentiation bridge from plasmablast to neutrophil, 
whereby the cells progressively lost expression of 
genes encoding canonical plasmablast markers 
(CD27, CD38, TNFRSF17) and acquired expression 
of genes encoding neutrophil granule proteins 
(defensin, elastase and myeloperoxidase) in the blood 
of COVID-19 patients with acute respiratory failure 
requiring mechanical ventilation. The authors did not 
observe any over-expression of pro-inflammatory 
cytokines by the peripheral monocytes and 
lymphocytes. Overall, the authors reported marked 
changes in the immune cell composition and 
phenotype in infection with specific immunological 
features of severe COVID-19 patients with acute 
respiratory distress syndrome (ARDS). 
Viruses deploy molecular mimicry to harness or 
disrupt cellular functions including modulation of 
immune responses. It was already shown that over 
140 host cellular proteins are structurally mimicked 
Box 1 — Different questions that are answered by transcriptomic 
studies reported 
1. What is the difference in blood transcripts of healthy subjects 
and those infected with SARS-CoV-2?1,2,4,5 
2. What is a blood-based signature of severity and poor outcome 
(e.g., severity, death)?1 
3. How do the gene expression change over time during the course 
of illness?1 
4. How do different tissues other than blood (lungs, nasopharynx) 
respond to infection?3,5,7,8 
5. How do different immune cells (leukocytes, monocytes, 
lymphocytes) respond to infection with SARS-CoV-2?1, 2, 4, 8 
6. Is there a cytokine storm in COVID-19?1-5,7 
*Some studies address multiple questions. 
 




by coronaviruses (CoV) with complement and 
coagulation pathways as targets of this strategy across 
all CoV strains
6
. Follow-up work by Ramlall and 
colleagues included a multimodal approach that 
combined clinical informatics, transcriptomics, 
genomics and molecular structure-function analysis to 
identify factors associated with poor clinical outcome 
of COVID-19
3
. First, analysis of the health records 
revealed that prior clinical history of coagulation or 
complement-activation disorders are risk factors for 
SARS-CoV-2-associated morbidity and mortality. 
Second, transcriptome analysis of nasopharyngeal 
swabs from a large cohort (650 control + case) 
revealed enrichment of complement and coagulation 
pathway (Fig. 1). Additional genetic evidence made a 
compelling argument that complement and 
coagulation functions play a major role in the 
outcome of SARS-CoV-2 infection. 
Immune gene expression profiling was performed in 
three patients of COVID-19, one with severe and two 
with moderate illness
1
. Although the number of 
patients was small, blood samples were collected at 
multiple time points for each subject, thus enabling 
dissection of gene expression dynamics during the 
course of the illness. The authors made some key 
observations. First, in the severe case, there was 
increased cytokine expression, but timing of up-
regulation was variable. Most pro-inflammatory 
cytokines followed the lowest point in respiratory 
dysfunction suggesting that these were the 
consequence rather than cause of respiratory 
dysfunction. However, interleukin-1 (IL-1) signalling 
was observed early on, suggesting that IL-1 and related 
pro-inflammatory pathways may be prognostic markers 
and/or therapeutic targets for COVID-19. Second,  
pro-inflammatory response was intertwined with T cell 
activation leading to the dichotomy between viral 
clearance and exacerbation of disease. For example, the 
case with severe illness was associated with rapid viral 
clearance, but increased respiratory dysfunction and 
requirement for supplemental oxygen. On the other 
hand, the cases with moderate illness were consistently 
positive for SARS-CoV-2 suggesting failure of viral 
clearance by the host immune system.  
Lee and colleagues
4
 performed high-resolution 
transcriptome profiling (single-cell RNA seq) of PBMC 
 
 
Fig. 1 — Up-regulation of complement and coagulation cascades. Each node corresponds to a gene belonging to the KEGG pathway 
―Complement and Coagulation Cascade‖. Up-regulated genes are shown as red nodes in the pathway map. Data were extracted from3 and 
drawn using R and Bioconductor13 




from healthy subjects, influenza, COVID-19 of varying 
severity. Comparison was made between the host 
response to the two respiratory viruses (influenza and 
SARS-CoV-2) with an effort to better define the 
immune response in COVID-19. Prominently, a  
TNF-α/IL-1β-driven hyperinflammatory response was 
observed in patients with severe COVID-19, but not 
in patients with mild illness. They proposed that type 
I interferon response plays a key role in exacerbating 
inflammation in severe COVID-19. The finding of 
this study stands in contrast to that of other study
2
, 
who did not observe the up-regulation of 
proinflammatory cytokines. 
Liao and colleagues performed single-cell 
transcriptomic profiling of broncho-alveolar lavage 
fluids from SARS-CoV-2 patients of varying disease 
severity
7
. They observed an increased proportion of 
pro-inflammatory monocyte derived macrophage in 
patients with severe illness, and clonal expansion of 
CD8
+
 T cells in patients with moderate illness. 
Xiong and colleagues performed transcriptome 
profiling of broncho-alveolar lavage fluids and PBMC 
samples from COVID-19 patients and observed 
strong association between COVID-19 pathogenesis 
and excessive cytokine release such as CCL2/MCP-1, 
CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B
8
. 
Additionally, the authors suggested that lymphopenia 
(observed in COVID-19 patients) is possibly due to 
SARS-CoV-2-induced activation of apoptosis and p53 
signalling in lymphocytes. 
 
Sequencing platforms 
The studies cited here employed different platforms 
such as single cell RNA seq, bulk RNA seq, or more 
targeted approaches such as Nanostring nCounter. 
Often the choice of platform is linked with the 
question being asked by the investigators. The newer 
technology of single cell RNA sequencing provides 
data at a very high cellular granularity. However, this 
is an evolving technology with heterogeneous 
workflow and may lead to contradictory results
2,4
. 
Bulk RNA sequencing is a safer option, with  
well-established analysis pipeline and reproducible 
results. A well-established platform such as bulk 
RNA sequencing produces reproducible result, but is 
limited to coarse tissue level data. The Nanostring 
nCounter technology is especially suitable for 
evaluation of disease-specific signature gene set 
1
. 
A series of studies mentioned inthe preceding 
sections have generated extensive transcriptomic data 
from human subjects with COVID-19. The findings 
from these studies add up to a set of interesting 
observations and are summarized in (Table 1). Most 
commonly observed transcriptional alterations include 
that of cytokines, interferon and HLA II. Gene 
expression profiling can be de-convoluted to reason 
about the cellular source of the RNA. This has led to 
frequent reporting of differential immune cell 
abundance in the blood or tissue of COVID-19 
patients with varying illness severity. Further, innate 
immune processes such as complement and 
coagulation have been shown to be significantly  
up-regulated in patients with COVID-19 illness. 
Three important motifs emerge from the cumulative 
evidence collected by the transcriptomic studies. 
 
Cytokine storm 
Multiple transcriptome analyses from blood 
immune cells and lung tissue suggest the presence of 
higher level of cytokines in COVID-19 patients
1,3,5,8
. 
This is also consistent with the immunophenotyping 
data
4
 and the prevailing paradigm of an uncontrolled 
pro-inflammatory cytokine storm being the principal 
driver of the disease. However, cytokine storm was 
not observed in all COVID-19 cohorts. Wilk and 
colleagues observed no evidence of a cytokine storm 
in the patients of COVID-19
2
. Also, different 
cytokines were identified as the dominant driver of 
pathophysiology by different studies. IL-1, IL-6 and 
TNF- have all been implicated in the disease 
progression and outcome of COVID-19, but there is 
no consensus. Of note, two single cell RNA seq 
studies have conspicuously differed on the finding of 
pro-inflammatory cytokines such as IL-1 and TNF- 
in COVID-19
2,4
. Further, there is significant 
difference in the dynamics of multiple cytokine gene 
expression during COVID-19 disease, where IL-1 
signalling preceded (while other cytokines succeeded) 
the respiratory function nadir in a case of severe 
COVID-19 illness
1
. While COVID-19 illness cannot 
be completely explained in terms of a ―cytokine 
storm‖, unravelling the interaction between specific 
cytokines and biologically relevant immuno-
inflammatory processes are likely to impact  
precise therapeutics (e.g., anti-IL-6 Tocilizumab) for 
COVID-19. 
 
Immune cells in COVID-19 
Severe COVID-19 illness is strongly associated 
with lymphopenia and neutrophilia
9
. Apoptosis and 
p53 signalling have been implicated in lymphopenia
8
. 
However, there is targeted expansion of CD8
+
 T cells 




in specific tissues such as lungs
7
 and T cell activation 
in blood
1
. Apart from increase in the neutrophil count, 
there is up-regulation of circulating chemo attractants 
CXCL2, CXCL8 (for neutrophils), CCL2, CCL8 (for 
monocytes), etc. in COVID-19 patients
5
. Moreover, 
not all neutrophils observed in the severe COVID-19 
illness are mature neutrophils. There is evidence of 
increased number of ―developing‖ neutrophils in 
patients of severe COVID-19 with respiratory 
distress, either derived from plasma blasts, as a 
consequence of emergency granulopoiesis
2
, or by 
another mechanism
10
. Of note, their role in severe and 
critical COVID-19 illness remains to be unmasked. 
Complements and Coagulation pathway 
Multi-modal transcriptomic analysis revealed that 
SARS-CoV-2 engages robust activation of complement 
and coagulation cascades
3,8
. Abnormal coagulative states 
predispose individuals to adverse outcomes associated 
with SARS-CoV-2 outcomes
11
. In the laboratory, 
hypercoagulable state is frequently encountered in the 
patients of COVID-19. A high level of D-dimer (a fibrin 
degradation product) is particularly associated with 
severity of illness and poor outcome. Up-regulation of 
complement pathway is strongly associated with 
coagulopathy and respiratory dysfunction
12
. The cellular 
and molecular pathways that communicate with 
Table 1 — Salient findings of some key transcriptomic studies on COVID-19 
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of IL1RA, IL-6 
Up-regulation 
of IL-6 response 
Interferon N.R. Heterogeneous 
IFN response 
Type I IFN  
up-regulated in 
severe patients 
N.R. N.R. No up-regulation  
of Type I,  
Type III IFN 
Up-regulation  
of Type-I IFN 
response 
HLA II Down Down N.R. N.R. N.R. N.R. N.R. 
Lymphocyte T cell 
activation 
N.R. N.R. Lymphopenia  








CD8+ T cells 
N.R. N.R. 




N.R. N.R. N.R. Up-regulation  






N.R. N.R. N.R. Up-regulation  
of complement 
cascade 
N.R. N.R. Up-regulation 
BALF-Broncho-alveolar lavage fluid; N.R.-Not reported; nCOV-COVID-19; PBMC-Peripheral Blood Mononuclear Cells 




complement and coagulation activation in COVID-19 is 
an active area of research. It is expected that new 
knowledge in this branch of innate immunity shall pave 
the way for precision therapy of those who are critically 
ill with SARS-CoV-2 infection.  
 
Conclusion 
In this article, we have discussed some recent 
transcriptomic studies performed in the patients  
of COVID-19. The studies were conducted with 
cutting-edge technology and provided insight into the 
disease biology of human infection by SARS-CoV-2. 
First, different cytokines were reported to be  
up-regulated by different authors. Also, the expression 
of these cytokines had a dynamic component vis-à-vis 
clinical parameters, especially respiratory function in 
severe COVID-19 illness. Therefore, instead of a broad 
cytokine storm, specific and transient cytokine 
expression is more likely a driver of the down-stream 
molecular and cellular modules. Second, neutrophilia 
and lymphopenia are clearly evident from the 
transcriptomic studies. While gene expression 
consistent with apoptosis and p53 signalling underlie 
lymphopenia, neutrophilia is associated with increased 
abundance of immature or developing neutrophils in 
the blood of the severe COVID-19 patients. This novel 
finding warrants deeper investigation and shall likely 
lead to novel mechanistic insight and therapeutic 
advances. Third, complement and coagulation cascades 
are progressively up-regulated in critically ill patients 
with COVID-19. A hypercoagulable state is a predictor 
of poor outcome of COVID-19. Along this line, 
interactions of the complement pathway with 
coagulation cascade and with other immune-
inflammatory processes are being pursued intensively 
and are likely to generate actionable knowledge for 
precise therapy of COVID-19 patients. In conclusion, 
while transcriptomic profiling has provided valuable 
insight into COVID-19 disease processes, the future 
looks brighter with integration of clinical metadata and 
gene expression profiling that shall produce 
meaningful data generated in a realistic time-frame for 
the treating physician. Further, with increased 
automation of clinical transcriptomics and related 
technologies that generate high-dimensional data in a 
narrow time window, application of artificial 
intelligence shall revolutionize critical care for 
infectious diseases such as COVID-19 and sepsis.  
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